Zoetis Inc. $ZTS Holdings Lowered by Mackenzie Financial Corp

Mackenzie Financial Corp lowered its stake in Zoetis Inc. (NYSE:ZTS) by 29.6% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 1,270,308 shares of the company’s stock after selling 534,473 shares during the quarter. Mackenzie Financial Corp owned approximately 0.29% of Zoetis worth $185,871,000 as of its most recent filing with the Securities and Exchange Commission.

Other institutional investors have also recently bought and sold shares of the company. CIBC Asset Management Inc increased its position in shares of Zoetis by 4.3% in the third quarter. CIBC Asset Management Inc now owns 251,495 shares of the company’s stock worth $36,745,000 after acquiring an additional 10,434 shares in the last quarter. Mitsubishi UFJ Trust & Banking Corp boosted its stake in Zoetis by 6.5% in the 3rd quarter. Mitsubishi UFJ Trust & Banking Corp now owns 295,482 shares of the company’s stock worth $43,235,000 after purchasing an additional 18,040 shares during the period. Ninety One UK Ltd boosted its stake in Zoetis by 19.6% in the 3rd quarter. Ninety One UK Ltd now owns 1,119,132 shares of the company’s stock worth $163,751,000 after purchasing an additional 183,686 shares during the period. Quilter Plc grew its position in Zoetis by 10.2% during the 3rd quarter. Quilter Plc now owns 438,959 shares of the company’s stock worth $64,228,000 after purchasing an additional 40,615 shares in the last quarter. Finally, Swedbank AB raised its stake in Zoetis by 60.4% during the 3rd quarter. Swedbank AB now owns 2,436,888 shares of the company’s stock valued at $356,565,000 after purchasing an additional 917,598 shares during the period. Hedge funds and other institutional investors own 92.80% of the company’s stock.

Zoetis Stock Down 1.5%

Zoetis stock opened at $120.52 on Wednesday. The company has a debt-to-equity ratio of 2.71, a current ratio of 3.03 and a quick ratio of 1.94. Zoetis Inc. has a fifty-two week low of $115.25 and a fifty-two week high of $172.23. The company’s 50 day simple moving average is $125.87 and its 200 day simple moving average is $132.39. The firm has a market capitalization of $50.87 billion, a price-to-earnings ratio of 20.02, a PEG ratio of 1.87 and a beta of 0.95.

Zoetis (NYSE:ZTS) last announced its quarterly earnings results on Thursday, February 12th. The company reported $1.48 earnings per share for the quarter, beating analysts’ consensus estimates of $1.40 by $0.08. The firm had revenue of $2.39 billion for the quarter, compared to analyst estimates of $2.36 billion. Zoetis had a net margin of 28.24% and a return on equity of 62.02%. The business’s revenue was up 3.0% on a year-over-year basis. During the same quarter in the previous year, the firm posted $1.40 earnings per share. Zoetis has set its FY 2026 guidance at 7.000-7.100 EPS. As a group, sell-side analysts anticipate that Zoetis Inc. will post 6.07 EPS for the current year.

Zoetis Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, June 2nd. Investors of record on Monday, April 20th will be issued a dividend of $0.53 per share. The ex-dividend date of this dividend is Monday, April 20th. This represents a $2.12 dividend on an annualized basis and a dividend yield of 1.8%. Zoetis’s payout ratio is presently 35.22%.

Analyst Ratings Changes

A number of research analysts have recently weighed in on ZTS shares. Piper Sandler reiterated a “neutral” rating and set a $135.00 price target (down from $190.00) on shares of Zoetis in a report on Thursday, January 22nd. KeyCorp assumed coverage on shares of Zoetis in a research note on Thursday, November 20th. They issued a “sector weight” rating for the company. HSBC set a $140.00 price target on Zoetis in a report on Wednesday, December 10th. Leerink Partners reiterated a “market perform” rating on shares of Zoetis in a research note on Tuesday. Finally, Barclays started coverage on Zoetis in a research report on Monday, December 8th. They issued an “equal weight” rating and a $136.00 price objective for the company. Six research analysts have rated the stock with a Buy rating, seven have given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Hold” and an average target price of $152.91.

About Zoetis

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.